<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01167738</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000681691</org_study_id>
    <secondary_id>PACT-17</secondary_id>
    <secondary_id>2010-020979-23</secondary_id>
    <nct_id>NCT01167738</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Metformin Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer</brief_title>
  <acronym>PACT-17</acronym>
  <official_title>A Randomized Phase II Study of Chemotherapy Â± Metformin in Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor
      cells, either by killing the cells or by stopping them from dividing. Giving more than one
      drug (combination chemotherapy) may kill more tumor cells. Metformin hydrochloride may stop
      the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not
      yet known if combination chemotherapy is more effective with or without metformin
      hydrochloride in treating patients with metastatic pancreatic cancer.

      PURPOSE: This randomized phase II trial is studying giving cisplatin, epirubicin
      hydrochloride, capecitabine, and gemcitabine hydrochloride together with metformin
      hydrochloride to see how well it works compared to cisplatin, epirubicin hydrochloride,
      capecitabine, and gemcitabine hydrochloride alone in treating patients with metastatic
      pancreatic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To assess the therapeutic activity of chemotherapy comprising cisplatin, epirubicin
           hydrochloride, capecitabine, and gemcitabine hydrochloride with versus without metformin
           hydrochloride in terms of 6-month progression-free survival in patients with metastatic
           pancreatic cancer.

      Secondary

        -  To assess the overall survival of patients treated with this regimen.

        -  To assess the response rate in patients treated with this regimen.

        -  To assess the duration of response in patients treated with this regimen.

        -  To assess the toxicity in patients treated with this regimen.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive cisplatin, epirubicin hydrochloride, and gemcitabine
           hydrochloride on days 1 and 15. Patients will also receive capecitabine and metformin
           hydrochloride on days 1-28. Treatment repeats every 4 weeks for up to 6 courses in the
           absence of disease progression or unacceptable toxicity.

        -  Arm II: Patients receive cisplatin, epirubicin hydrochloride, gemcitabine hydrochloride,
           and capecitabine as in arm I. Treatment repeats every 4 weeks for up to 6 courses in the
           absence of disease progression or unacceptable toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    concern of detrimental effect
  </why_stopped>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival at 6 months</measure>
    <time_frame>every 2 months</time_frame>
    <description>CT scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>every 14 days during therapy; every 3 months thereafter</time_frame>
    <description>outpatient visit, phone interview</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>every 2 months</time_frame>
    <description>CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>every 2 weeks</time_frame>
    <description>outpatient visit, laboratory findings</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>PEXG regimen + metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cisplatin and epirubicin at 30 mg/mq on days 1 and 15, capecitabine at 1250 mg/mq days 1-28, gemcitabine at 800 mg/mq on days 1 and 15, Metformin at 2 g days 1-28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEXG regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cisplatin and epirubicin at 30 mg/mQ on days 1 and 15, capecitabine at 1250 mg/mq days 1-28, gemcitabine at 800 mg/mq on days 1 and 15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>1250 mg/mq days 1-28 every 4 weeks</description>
    <arm_group_label>PEXG regimen + metformin</arm_group_label>
    <arm_group_label>PEXG regimen</arm_group_label>
    <other_name>XELODA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>30 mg/mq on days 1 and 15 every 4 weeks</description>
    <arm_group_label>PEXG regimen + metformin</arm_group_label>
    <arm_group_label>PEXG regimen</arm_group_label>
    <other_name>cisplatino TEVA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin</intervention_name>
    <description>30 mg/mq on days 1 and 15 every 4 weeks</description>
    <arm_group_label>PEXG regimen + metformin</arm_group_label>
    <arm_group_label>PEXG regimen</arm_group_label>
    <other_name>farmorubicina</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>800 mg/mq on days 1 and 15 every 4 weeks</description>
    <arm_group_label>PEXG regimen + metformin</arm_group_label>
    <arm_group_label>PEXG regimen</arm_group_label>
    <other_name>GEMZAR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>2 g days 1-28 every 4 weeks</description>
    <arm_group_label>PEXG regimen + metformin</arm_group_label>
    <other_name>glucophage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed pancreatic adenocarcinoma

               -  Metastatic (stage IV) disease

          -  Measurable disease

          -  No symptomatic brain metastases

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status 60-100%

          -  Not pregnant or nursing

          -  Adequate bone marrow, liver and kidney function

          -  No previous or concurrent malignancies at other sites except for surgically cured
             carcinoma in-situ of the cervix, basal cell or squamous cell carcinoma of the skin, or
             other neoplasms without evidence of disease within the past 5 years

          -  No multiple severe diseases which would compromise safety (i.e., cardiac failure,
             previous myocardial infarction within the past 4 months, cardiac arrhythmia, or
             history of psychiatric disabilities)

          -  No alcohol abuse

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy or metformin

          -  No other concurrent experimental drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Reni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Scientifico H. San Raffaele</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Scientifico H. San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2010</study_first_submitted>
  <study_first_submitted_qc>July 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2010</study_first_posted>
  <last_update_submitted>April 23, 2015</last_update_submitted>
  <last_update_submitted_qc>April 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Michele Reni</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

